GlassScriptPhysician profile
Amanda M Boyle
NPI 1184212912
$869.86
in general payments reported to CMS, 2019-2025
21 companies · $17.76 in 2025
The $17.76 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $350 · 2022: $374 · 2023: $19.76 · 2024: $108 · 2025: $17.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $145.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $165.73 | 2021-2024 | Enhertu |
| Merck Sharp & Dohme LLC | $124.03 | 2021-2024 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $93.71 | 2021-2022 | |
| Seagen INC. | $64.18 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $51.42 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $45.00 | 2022 | |
| Amgen INC. | $33.99 | 2021-2024 | Tezspire |
| Incyte Corporation | $29.15 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.09 | 2022 | |
| Gilead Sciences, INC. | $28.76 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $28.22 | 2021-2024 | Calquence |
| Emmaus Medical, INC. | $22.88 | 2022 | |
| Rigel Pharmaceuticals, INC. | $21.96 | 2024 | Rezlidhia, Tavalisse |
| Coherus Oncology, INC. | $21.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.76 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Autolus INC | $17.76 | 2025 | |
| Genmab U.S., INC. | $15.75 | 2022 | |
| Emd Serono, INC. | $14.80 | 2021 | |
| Janssen Biotech, INC. | $14.22 | 2021 | |
| Pfizer INC. | $13.97 | 2021 | |
| Eisai INC. | $13.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.